Drug Molecule Information Melanoma is characterized by mutation of a variety of genes. Dabrafenib is an approved treatment for metastatic melanoma in the patients with BRAF V600E mutation. This article aims to provide brief information about this drug. Dabrafenib is a kinase inhibitor indicated as a single agent for the treatment of metastatic melanoma.
It selectively inhibits some mutated forms of protein kinase B-raf (BRAF). BRAF V600 mutations result in constitutive activation of the BRAF pathway, thus, through BRAF inhibition, dabrafenib inhibits tumor cell growth. Indication and Usage Limitations: Dabrafenib is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Dabrafenib in combination with trametinib is indicated for the treatment of patients with…
